Clinical Trials Search at Vanderbilt-Ingram Cancer Center
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse / Refractory Multiple Myeloma
Multiple Cancer Types
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse / refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Multiple Myeloma, Phase I